JP Morgan downgrades Abbott India to 'neutral' citing growth headwinds

Abbott India

15/04/2026 04:52

** JP Morgan downgrades Abbott India ABOT.NS to "neutral" from "overweight" and slashes PT to 27,500 rupees from 34,000 rupees

** Brokerage cites growth headwinds for drugmaker due to limited new product launches and phasing out of its largest insulin brand - Mixtard

** Stock largely flat on the day

** Adds, three MD resignations in four years increase uncertainty around strategic direction and growth priorities

** Avg rating of seven analysts on ABOT at "buy"; median PT is 34,030 rupees - data compiled by LSEG

** YTD, stock down 11% vs 2.1% drop in pharma index .NIPHARM

 (Reporting by Kashish Tandon in Bengaluru)

 ((Kashish.tandon@thomsonreuters.com))